Companies › Fortvita Biologics (USA)Inc.
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IBI3001 | – | Phase 1 | Locally Advanced Solid Tumor | Dec 2026 |
| IBI3003 | – | Phase 1 | Multiple Myeloma | Jun 2027 |
| IBI3020 anti-CEACAM5 monoclonal antibody-drug conjugate | CEACAM5 | Phase 1 | Solid Tumors | Dec 2027 |
| IBI3032 | – | Phase 1 | Healthy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07120425 | IBI3032 | Phase 1 | Healthy | Other | Nov 2025 |
| NCT06349408 | IBI3001 | Phase 1 | Locally Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07336472 | IBI3003 | Phase 1 | Multiple Myeloma | Oncology | Jun 2027 |
| NCT06963281 | IBI3020 | Phase 1 | Solid Tumors | Oncology | Dec 2027 |
Chongqing Precision Biotech Beijing Biotech Merck KGaA A2 Biotherapeutics Roche Bristol-Myers Squibb LaNova Medicines Genmab Harbour BioMed (Guangzhou) Kivu Bioscience
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.